Cognition is thrilled to announce that we have successfully raised $185 million in our latest funding round, a significant milestone that underscores the tremendous potential of our pioneering technology. As the makers of Devin, the world's first AI software engineer, we are at the forefront of applied AI innovation. Our mission is to develop collaborative AI teammates that empower engineering teams, allowing engineers to shift their focus from mundane coding tasks to more complex and engaging challenges. This newfound capital will accelerate our research and development efforts, enabling us to enhance Devin’s capabilities and expand our suite of end-to-end software agents to address a broader range of engineering needs. With this significant investment, we aim to foster a culture of creativity and innovation within teams, ultimately empowering them to strive for more ambitious goals. As we continue to build cutting-edge AI that integrates seamlessly with human ingenuity, we remain committed to pushing the boundaries of what’s possible in software engineering. This funding will not only support the growth of our technology but also enhance our recruitment efforts, ensuring we can attract the best talent to join our mission of transforming the engineering landscape. We extend our heartfelt gratitude to our investors for believing in our vision, and we look forward to the exciting journey ahead as we revolutionize the way software is developed. Stay tuned for more updates as we evolve and expand our capabilities to create the future of intelligent engineering!
Cognition Secures $185 Million in Series B Funding to Enhance AI Software Engineering Capabilities
Recently funded · $185.0M Series bTechnology/Software
Get the full Cognition company profile
Access contacts, investors, buying signals & more
Other recently funded companies
View all
Mach42
Mach42™ is a spinout company from Oxford University, delivering the next step-change in simulation acceleration, an early-stage software company developing state-of-the-art machine learning and Artificial Intelligence technology to simplify, automate, and accelerate simulation tasks. We leverage proprietary neural network technology to accelerate expensive calculations, and we do it with minimal data and high accuracy, providing many orders of magnitude speedup in verification acceleration. Our platform is already delivering a substantial competitive advantage to our early customers.
$9.1M Seed
today
Transcripta Bio
We are focused on drug discovery at unprecedented speed and scale, with lower risk and higher certainty across multiple diseases in parallel. With data from hundreds of millions of experiments, we have mapped the effects of thousands of compounds on gene expression to discover new therapies. Our Drug-Gene Atlas maps molecular structure and drug action to the whole cell transcriptome, revealing therapeutic candidates that rebalance gene expression to treat disease. Our proprietary artificial intelligence modeling suite, Conductor AI, used our Drug-Gene Atlas to discover and predict the effects of new drugs at transcriptome scale.
Other recent Series b rounds
Companies that recently closed a Series b round.
| # | Company | Round | Amount | Date |
|---|---|---|---|---|
| 1 |  Shield AI United States | Series b | $15.0M | today |
| 2 |  ć ŞĺĽŹäĽšç¤ľT2 Japan | Series b | $33.3M | 1d ago |
| 3 |
